[{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"06560225-2b42-48b3-bbbc-b9ae314d8a0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040231","created_at":"2021-02-01T11:53:19.132Z","updated_at":"2024-07-02T16:34:26.088Z","phase":"Phase 1","brief_title":"Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma","source_id_and_acronym":"NCT04040231","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"343f189d-c6cb-4a8b-b082-0b802260f284","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320809","created_at":"2022-04-11T13:52:57.991Z","updated_at":"2024-07-02T16:35:31.834Z","phase":"Phase 1","brief_title":"Study of 3D189 in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05320809","lead_sponsor":"3D Medicines","biomarkers":" WT1","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-25"},{"id":"6cd6fea1-b47e-41c8-8a34-ff357b707a61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02737787","created_at":"2021-01-18T13:24:34.815Z","updated_at":"2024-07-02T16:35:51.110Z","phase":"Phase 1","brief_title":"A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02737787","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • MUC16 • CTAG1B","pipe":" | ","alterations":" WT1 expression • CTAG1B expression • WT1 positive","tags":["WT1 • MUC16 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • CTAG1B expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-07"},{"id":"baa7e829-6923-4d37-b1b8-aed8bbc1d4c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827137","created_at":"2021-01-29T07:04:33.744Z","updated_at":"2024-07-02T16:36:51.495Z","phase":"","brief_title":"WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT01827137","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" IFNG • WT1 • CD4","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["IFNG • WT1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Unknown status","enrollment":" Enrollment 22","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2020-01-10"},{"id":"cdbb0b72-4989-4bfe-b215-24f0d0781366","acronym":"","url":"https://clinicaltrials.gov/study/NCT01890980","created_at":"2021-01-18T08:29:29.880Z","updated_at":"2024-07-02T16:36:59.765Z","phase":"Phase 2","brief_title":"Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134","source_id_and_acronym":"NCT01890980","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" WT1 • CSF2","pipe":"","alterations":" ","tags":["WT1 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2019-05-10"},{"id":"937cd282-98ca-4cd4-be39-75fd046925ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01266083","created_at":"2021-01-18T05:07:05.651Z","updated_at":"2024-07-02T16:37:04.963Z","phase":"Phase 2","brief_title":"WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT01266083","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" FLT3 • NPM1 • WT1","pipe":" | ","alterations":" NPM1 mutation","tags":["FLT3 • NPM1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2018-11-30"},{"id":"0319ca73-9379-4e46-9216-1095fcc78f0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01265433","created_at":"2021-01-18T05:06:32.789Z","updated_at":"2024-07-02T16:37:05.585Z","phase":"Phase 2","brief_title":"WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy","source_id_and_acronym":"NCT01265433","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" WT1 • CSF2","pipe":"","alterations":" ","tags":["WT1 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 12/21/2010","start_date":" 12/21/2010","primary_txt":" Primary completion: 07/25/2017","primary_completion_date":" 07/25/2017","study_txt":" Completion: 07/25/2017","study_completion_date":" 07/25/2017","last_update_posted":"2018-11-05"},{"id":"ee17c56b-100b-4f4d-add7-d4b4a993c0e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01842139","created_at":"2021-01-18T08:12:34.440Z","updated_at":"2024-07-02T16:37:13.134Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission","source_id_and_acronym":"NCT01842139","lead_sponsor":"University of Chicago","biomarkers":" CD8 • IFNG • WT1 • FOXP3","pipe":" | ","alterations":" FOXP3 expression","tags":["CD8 • IFNG • WT1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/05/2011","start_date":" 12/05/2011","primary_txt":" Primary completion: 02/02/2015","primary_completion_date":" 02/02/2015","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2018-03-09"}]